MYX mayne pharma group limited

Lacking on detail. This is the 2nd Complete Response Letter FROM...

  1. 2,519 Posts.
    lightbulb Created with Sketch. 214
    Lacking on detail. This is the 2nd Complete Response Letter FROM THE FDA. Is it something new or is it an inadequate response to Mayne's response to the 1st Complete Response Letter? It is a positive that the manufacturing component of the ANDA has been considered approvable as that is the key part of an ANDA. What can be tricky with generics is the "bioequivalence" data, but if there was an issue that would have been raised in the 1st CRL.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.00
Change
-0.080(1.57%)
Mkt cap ! $406.2M
Open High Low Value Volume
$5.08 $5.10 $4.95 $1.426M 285.1K

Buyers (Bids)

No. Vol. Price($)
1 50 $5.00
 

Sellers (Offers)

Price($) Vol. No.
$5.02 259 1
View Market Depth
Last trade - 16.10pm 30/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.